Related Experiment Video
Updated: Feb 13, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
DRR1 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via regulating AKT activation
Yu-Shui Ma1, Zhi-Jun Wu2, Rui-Zhen Bai3
1Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, College of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China.
Abstract:
Metastatic invasion is the primary cause of treatment failure for GBM. EMT is one of the most important events in the invasion of GBM; therefore, understanding the molecular mechanisms of EMT is crucial for the treatment of GBM. In this study, high expression of DRR1 was identified to correlate with a shorter median overall and relapse-free survival. Loss-of-function assays using shDRR1 weakened the invasive potential of the GBM cell lines through regulation of EMT-markers. The expressions of p-AKT were significantly decreased after DRR-depletion in SHG44 and U373 cells. Moreover, the invasion was inhibited by the AKT inhibitor, MK-2206. The expression of Vimentin, N-cadherin, MMP-7, snail and slug was significantly inhibited by MK-2206, while the expression of E-cadherin was upregulated. Our results provide the first evidence that DRR1 is involved in GBM invasion and progression possibly through the induction of EMT activation by phosphorylation of AKT.
Insights
High expression of DRR1 correlates with poor survival in glioblastoma (GBM). DRR1 depletion inhibits GBM invasion by regulating epithelial-mesenchymal transition (EMT) and AKT signaling.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Mechanisms
Background:
- Metastatic invasion is a key factor in glioblastoma (GBM) treatment failure.
- Epithelial-mesenchymal transition (EMT) is critical for GBM invasion.
- Understanding EMT's molecular drivers is vital for developing new GBM therapies.
Purpose of the Study:
- To investigate the role of DRR1 in GBM invasion and progression.
- To elucidate the molecular mechanisms underlying DRR1's function in GBM.
Main Methods:
- Correlative analysis of DRR1 expression with patient survival data.
- Loss-of-function assays using short hairpin RNA (shRNA) targeting DRR1 (shDRR1) in GBM cell lines.
- Assessment of EMT markers and AKT pathway activation (p-AKT).
- Pharmacological inhibition of AKT signaling using MK-2206.
Main Results:
- High DRR1 expression was associated with shorter overall and relapse-free survival in GBM patients.
- DRR1 depletion using shDRR1 reduced GBM cell line invasiveness by modulating EMT markers.
- DRR1 depletion led to decreased p-AKT levels in GBM cells.
- Inhibition of AKT signaling with MK-2206 suppressed invasion and altered EMT marker expression (Vimentin, N-cadherin, MMP-7, snail, slug, E-cadherin).
Conclusions:
- DRR1 plays a significant role in GBM invasion and progression.
- DRR1 may promote EMT activation through the phosphorylation of AKT.
- Targeting DRR1 or the AKT pathway presents a potential therapeutic strategy for GBM.
Related Concept Videos
Positive Regulator Molecules
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Eukaryotic Promoter Region
Cooperative Allosteric Transitions
Phase Transitions
Negative Regulator Molecules

